Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Accelerated Approval Decline? Too Early To Overinterpret US FDA Trend

Dec 15 2022

• By Michael McCaughan

up and down percentage — • Source: Shutterstock

Related Content

After ‘Clean’ User Fee Renewal, Will Programs Held Hostage Be Enough To Drive A Broader Reform Bill?

Sep 28 2022

Accelerated Approval In The US: It Really Is Rare Outside Of Oncology

Sep 09 2022

Amylyx’s Relyvrio: US FDA Review Shows Regulatory Flexibility Can Come In Many Forms

Nov 10 2022

Lecanemab Data On Benefit In Alzheimer’s Might Satisfy FDA – But What About Medicare?

Dec 01 2022

US FDA Says Confirmatory Trials Should Start Before Accelerated Approval But Is Not ‘Dogmatic’

Dec 01 2022

Accelerated Approval For Gene Therapies: FDA’s Wilson Bryan Offers A ‘Framework’

Oct 28 2022

US FDA Wants To Help Sponsors Generate Evidence CMS Needs, But Won't Be An Intermediary

Oct 24 2022

N Of 2: Reflections On The Makena, Avastin Accelerated Approval Withdrawal Hearings

Oct 21 2022

Related Companies

Mirati Therapeutics, Inc.

Merck & Co., Inc.

Genetix Biotherapeutics

Biogen, Inc.

Eisai Co., Ltd.

Amylyx Pharmaceuticals, Inc.

Additional Topics

United States Review Pathway Drug Approval Standards Drug Review Regulation BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window